{
    "clinical_study": {
        "@rank": "72406", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who\n      have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or\n      refractory solid tumor."
        }, 
        "brief_title": "Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors", 
        "completion_date": {
            "#text": "October 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Brain and Central Nervous System Tumors", 
            "Lymphoma", 
            "Neuroblastoma", 
            "Sarcoma", 
            "Unspecified Childhood Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Lymphoma", 
                "Nervous System Neoplasms", 
                "Neuroblastoma", 
                "Rhabdomyosarcoma", 
                "Central Nervous System Neoplasms", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the safety and side effects of gallium nitrate (GAN) when used as\n      an anticancer agent in pediatric patients with refractory solid tumors, including malignant\n      brain tumors, neuroblastoma, rhabdomyosarcoma, and non-Hodgkin's lymphoma. II. Evaluate\n      these side effects in these patients.\n\n      OUTLINE: Single-Agent Chemotherapy. Gallium Nitrate, GAN, NSC-15200.\n\n      PROJECTED ACCRUAL: At least 3 patients will be accrued at each dose studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Biopsy-proven rhabdomyosarcoma, non-Hodgkin's lymphoma, or other\n        solid tumor refractory to conventional therapy or for which no effective curative therapy\n        is known Re-biopsy required if disease recurs more than 2 years after initial diagnosis\n        recommended if radiographic abnormalities suggest tumor recurrence within 5 months of\n        completing radiotherapy or chemotherapy\n\n        PATIENT CHARACTERISTICS: Age: 21 and under at diagnosis Performance status: Karnofsky\n        50%-100% Life expectancy: More than 4 weeks Hematopoietic: (unless extensive bone marrow\n        involvement) ANC greater than 750 Platelets greater than 75,000 Hepatic: Not specified\n        Renal: Creatinine normal for age OR Glomerular filtration rate at least 50 mL/min per 1.73\n        square meters Other: Adequate nutritional status No serious uncontrolled infection No\n        pregnant or nursing women\n\n        PRIOR CONCURRENT THERAPY: At least 2 weeks since other anticancer therapy and recovered\n        Prior radiotherapy or surgery for symptomatic lesions allowed provided site of evaluable\n        disease remains untreated Prior bone marrow or stem cell transplantation allowed No\n        concurrent anticancer therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002543", 
            "org_study_id": "MCW-ARRC-22393", 
            "secondary_id": [
                "CDR0000063244", 
                "CHW-93/59", 
                "NCI-T93-0097D"
            ]
        }, 
        "intervention": {
            "intervention_name": "gallium nitrate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gallium nitrate"
        }, 
        "keyword": [
            "recurrent childhood rhabdomyosarcoma", 
            "recurrent childhood brain tumor", 
            "recurrent neuroblastoma", 
            "recurrent childhood lymphoblastic lymphoma", 
            "unspecified childhood solid tumor, protocol specific", 
            "recurrent childhood small noncleaved cell lymphoma", 
            "recurrent childhood large cell lymphoma"
        ], 
        "lastchanged_date": "July 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MCW-ARRC-22393"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Marlene & Stewart Greenebaum Cancer Center, University of Maryland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Boston Floating Hospital Infants and Children"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Medical College of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "GALLIUM NITRATE FOR THE TREATMENT OF MALIGNANT TUMORS, A PHASE I STUDY", 
        "overall_official": {
            "affiliation": "Medical College of Wisconsin", 
            "last_name": "Harry T. Whelan, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002543"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Medical College of Wisconsin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2007"
    }, 
    "geocoordinates": {
        "Boston Floating Hospital Infants and Children": "42.358 -71.06", 
        "Marlene & Stewart Greenebaum Cancer Center, University of Maryland": "39.29 -76.612", 
        "Medical College of Wisconsin": "43.039 -87.906"
    }
}